127. Breast. 2018 Jun 15;41:1-7. doi: 10.1016/j.breast.2018.06.001. [Epub ahead ofprint]Fluctuation of the left ventricular ejection fraction in patients withHER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.Jacquinot Q(1), Paget-Bailly S(2), Fumoleau P(3), Romieu G(4), Pierga JY(5),Espié M(6), Lortholary A(7), Nabholtz JM(8), Mercier CF(9), Pauporté I(10),Henriques J(11), Pivot X(12).Author information: (1)UPFR des Sports, Université de Bourgogne Franche-Comté, Besançon, France; EA3920: Marqueurs pronostiques et facteurs de régulation des pathologies cardiaqueset vasculaires, CHU Jean-Minjoz, Besançon, France. Electronic address:quentin.jacquinot@edu.univ-fcomte.fr.(2)INSERM UMR 1098: Unité de méthodologie et de qualité de vie en cancérologie,CHU Jean-Minjoz, Besançon, France. Electronic address: spaget@chu-besancon.fr.(3)Centre Georges François Leclerc, Dijon, France. Electronic address:pfumoleau@cgfl.fr.(4)Centre Val d'Aurelle, Montpellier, France. Electronic address:Romieu@icm.unicancer.fr.(5)Institut Curie, Paris, France. Electronic address: jean-yves.pierga@curie.fr.(6)Hôpital Universitaire Saint-Louis, Paris, France. Electronic address:marc.espie@sls.aphp.fr.(7)Centre Catherine de Sienne, Nantes, France. Electronic address:lortholary.alain@catherinedesienne.fr.(8)Centre Jean Perrin, Clermont-Ferrand, France. Electronic address:jmnabholtz@hotmail.com.(9)Institut National du Cancer, Boulogne, France. Electronic address:cfaure@institutcancer.fr.(10)Institut National du Cancer, Boulogne, France. Electronic address:ipauporte@institutcancer.fr.(11)INSERM UMR 1098: Unité de méthodologie et de qualité de vie en cancérologie, CHU Jean-Minjoz, Besançon, France. Electronic address:jhenriques@chu-besancon.fr.(12)Centre Paul Strauss, Strasbourg, France. Electronic address:XPivot@strasbourg.unicancer.fr.BACKGROUND: Cardiac toxicity with a decrease of the left ventricular ejectionfraction (LVEF) is the main side effect induced by trastuzumab. This studyreports the fluctuation of LVEF over the 12 months of adjuvant trastuzumab inPHARE trial (NCT00381901).METHODS: LVEF assessment was performed every 3 months while patients receivedtrastuzumab and after completion of treatment over the first 2 years and thenevery 6 months afterwards. The fluctuations of LVEF over time were described and a logistic regression model was performed investigating associated factors toLVEF perfect recovery at baseline value.RESULTS: A total of 1631 patients who received 12 months of trastuzumab fromPHARE trial, were considered in the analysis. A total of 13 881 LVEF measurementswere assessed. Baseline mean LVEF was 66.08% (standard error (SE): 0.15) and the mean relative LVEF decrease observed at 12-month was 3.61% (SE: 0.31). Noclinical characteristic was significantly associated to LVEF fluctuation. Aftercompletion of trastuzumab, the relative difference progressively disappeared withbeyond 30 months a relative difference value of 0.08% (SE: 0.42). Nevertheless,at 30 months, 48.53% of patients with available measures (379/781) did not fully recover their baseline LVEF value.CONCLUSION: The LVEF decreased during treatment with trastuzumab and rose upafter the completion of treatment without coming back to the initial values for asubstantial subset. These results would suggest investigating some strategiesaimed to improve the ability to achieve a full recovery.Copyright © 2018 Elsevier Ltd. All rights reserved.DOI: 10.1016/j.breast.2018.06.001 PMID: 29913374 